Skip to main content

Nuss John's Form 4 filing

Ventyx Biosciences, Inc. (VTYX) · filed Oct 4, 2023

Accession no.
0001209191-23-052120
Filed
Oct 4, 2023, 7:26 PM ET
Trade date
Oct 3, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $299.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Nuss JohnCIK 0001874108Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 3, 2023Common StockMOption exerciseAcquired+1,401$0.20+$280.2246,216Direct
Oct 3, 2023Common StockMOption exerciseAcquired+7,972$3.54+$28,220.88254,188Direct
Oct 3, 2023Common StockMOption exerciseAcquired+627$8.04+$5,041.08254,815Direct
Oct 3, 2023Common StockSSaleDisposed−9,277$29.94F2−$277,725.55245,538Direct
Oct 3, 2023Common StockSSaleDisposed−723$30.72F3−$22,207.31244,815Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 3, 2023Common StockMOption exerciseDisposed−1,401$0.00$05,377Direct
Oct 3, 2023Common StockMOption exerciseDisposed−7,972$0.00$00Direct
Oct 3, 2023Common StockMOption exerciseDisposed−627$0.00$0192,777Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average share price of an aggregate total of 9,277 shares sold in the price range of $29.24 to $30.205. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average share price of an aggregate total of 723 shares sold in the price range of $30.255 to $30.965. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)